Female-led Austrian biotech developing STAT5 inhibitors for AML — seed stage
RIANA Therapeutics has raised $259K in total funding. The most recent round was Seed. The last funding was announced in January 2025.
RIANA Therapeutics's investors include KHAN Technology Transfer Fund.
RIANA Therapeutics is headquartered in Vienna, Austria.
Female-led Austrian biotech developing STAT5 inhibitors for AML — seed stage
RIANA Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RIANA Therapeutics — Funding & Investors." VCBacked, January 1, 2025, https://www.vcbacked.co/company/riana-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). RIANA Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/riana-therapeutics
{{cite web |title=RIANA Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/riana-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated